Cigna's 84.5% Medical Ratio Splits From the Medicare Advantage Trend Story

Cigna's medical care ratio ran to 84.5% in the second quarter of 2026, seven points below Humana's 91.2% and five points below Elevance Health's 89.7% (The Cigna Group, July 30, 2026; Humana, July 29, 2026). That gap is not simply a commercial carrier having a good quarter. It is where 2026's cost-trend pressure is actually concentrated, and it is concentrated almost entirely in Medicare Advantage.

The same week every large managed-care company reported cost trend running "high single digit" or worse, Cigna's commercial and specialty-weighted book posted a medical care ratio that would have been a strong result even in the low-trend years before the 2024 cost break. Chief Financial Officer Ann Dennison told analysts the quarter's medical costs were "slightly favorable to expectations... reflecting lower outpatient trends, including lower surgical spend" (Cigna Q2 2026 earnings call, July 30, 2026), even as CEO Brian Evanko acknowledged the broader environment was still running hot: "We continue to see high single digit type cost trends, persistently elevated cost trend levels, not a significant deceleration and no acceleration" (Cigna Q2 2026 earnings call, July 30, 2026). Both statements are true at once, and reconciling them is the actuarial story of the quarter.

The 84.5% Print: Softer Surgical and Outpatient Spend in a Commercial Book

Cigna Healthcare's medical care ratio rose to 84.5% from 83.2% a year earlier, a comparison the company attributed primarily to lapping higher ACA risk-adjustment benefits recorded in the Individual and Family Plans business in the second quarter of 2025, not to underlying utilization deterioration (Cigna Q2 2026 earnings call, July 30, 2026). Segment revenue reached $11.8 billion, up 10% year over year, and Cigna Healthcare's pretax adjusted earnings were $1,276 million for the quarter, keeping the segment on pace with its raised full-year floor of at least $4,550 million (The Cigna Group, July 30, 2026). Total company revenue for the quarter was $71.7 billion, adjusted earnings per share were $7.78, and the board raised full-year adjusted EPS guidance to at least $30.45, up $0.10 from the prior floor of $30.35 (The Cigna Group, July 30, 2026).

What is notable is the driver Dennison named: not pharmacy, not primary care, but softer outpatient spending and specifically lower surgical volume. Surgical utilization is the line item that swings hardest with deferred-care catch-up in the years following a demand shock, and a book running cooler on elective and outpatient surgical volume in mid-2026 suggests that whatever backlog effect had been propping up utilization since 2023 has largely worked through Cigna's commercial population. That reading is consistent with Cigna's full-year 2026 medical care ratio guidance range of 83.7% to 84.7% (Cigna Q2 2026 earnings call, July 30, 2026), a band that assumes the second quarter's favorability is not a one-off.

Four Carriers, One Trend Narrative, Four Very Different Ratios

Set next to its peers, Cigna's print is the outlier on the low side of the 2026 managed-care reporting season. UnitedHealth's Q2 2026 medical care ratio fell to 86.7% from 89.4% a year earlier, a result Forbes attributed to benefit redesign, pricing discipline, and continued exits from unprofitable ACA and Medicare Advantage markets, extending the margin-recovery arc this site tracked when UnitedHealth and Elevance split the Q2 recovery. Elevance's benefit expense ratio ran to 89.7%, up 80 basis points year over year, which the company attributed to "elevated medical cost trends in Government businesses offset in part by improved Individual ACA performance" (Elevance Health, July 14, 2026). Humana's Insurance segment benefit ratio came in at 91.2%, in line with management's own guidance of "slightly above 91 percent," as individual Medicare Advantage membership surged roughly 25% year over year and drove consolidated revenue to $40.9 billion (Humana, July 29, 2026).

Carrier	Q2 2026 medical/benefit ratio	Year-over-year change	Book weighting
Cigna Healthcare	84.5%	+130 bps	Commercial, specialty, IFP
UnitedHealth	86.7%	−270 bps	Diversified, MA and commercial
Elevance Health	89.7%	+80 bps	Government-heavy, Medicaid and Medicare
Humana	91.2%	In line with guidance	Medicare Advantage-concentrated

Sources: The Cigna Group, Forbes/UnitedHealth Group, Elevance Health, Humana Inc., all Q2 2026 disclosures. Direction of change is not comparable across carriers on a like-for-like basis given differing book mix and prior-year bases.

The pattern across all four prints is the same: the closer a book sits to Medicare Advantage, the hotter the ratio, and the closer it sits to commercial group and specialty business, the cooler it runs. That is not a new observation in isolation, but the magnitude this quarter, a spread of nearly 700 basis points between Cigna and Humana on ratios reported within 48 hours of each other, is wide enough to matter for how actuaries frame the "cost trend" conversation for 2027 pricing. There is no single 2026 cost trend number. There are at least two trend regimes running simultaneously inside the same reporting season, split roughly along payer type.

Why a Commercial Book Runs Cooler Than a Medicare Book

The mechanical reasons a commercial-weighted book prints a lower ratio than an MA-weighted one are structural, not just cyclical. Commercial group plans carry member cost-sharing, deductibles and coinsurance, that is materially higher than the near-first-dollar coverage typical of MA supplemental benefit designs, which dampens paid claims per member relative to allowed cost. Commercial populations skew younger and are actively underwritten and experience-rated at each renewal, giving carriers a faster repricing lever than MA plans get through the annual CMS bid cycle. And MA reimbursement runs off a Medicare fee-for-service benchmark that has itself been running hot on physician and outpatient facility fee updates, a different cost driver than the negotiated commercial network rates Cigna's book is exposed to.

Those structural differences do not fully explain a 700 basis point spread on their own; some of it is genuine trend divergence. Specialty pharmacy and biologic drug spend, concentrated in employer and IFP populations with richer formularies, has been a commercial-side pressure that MA plans partially offset through utilization management and narrower Part D formularies. But Cigna's own commentary, softer surgical and outpatient spend specifically, points toward a population effect: employer-sponsored members who deferred elective procedures during 2023 and 2024 appear to have largely completed that catch-up, while MA's older, sicker, more acute population continues to generate the surgical and inpatient volume growth that drove Humana's and Elevance's higher ratios. A pricing actuary should read the Cigna print less as "cost trend is moderating" and more as "cost trend moderated first, and furthest, in the segment of the market with the most cost-sharing and the fastest repricing cycle."

The Reserving Read: Does 84.5% Hold Into the Second Half?

Cigna did not describe the quarter's favorability as reserve-driven. Dennison specifically walked through the stop-loss book, the segment most exposed to high-dollar claimant volatility, and reported no meaningful adverse signal: "We're tracking in line with expectations, was not a variance driver in the second quarter... We've seen stable frequency trends in high-cost claimants across multiple attachment point levels" (Cigna Q2 2026 earnings call, July 30, 2026). A stable stop-loss book is a meaningful data point for a reserving actuary because specific stop-loss claims are exactly where a hidden trend acceleration would surface first, in the tail of the claim distribution before it shows up in the aggregate loss ratio. Stable frequency at multiple attachment points argues against the favorable Q2 print being an artifact of large-claim timing that reverses in the third or fourth quarter.

That said, the guidance range itself, 83.7% to 84.7% for the full year, is asymmetric around the 84.5% actual. A print at the top of that band in the second quarter implies management is not extrapolating the full favorability forward; the midpoint of the range sits below the quarter's actual result, which is a conservative posture consistent with a company unwilling to bank a single quarter's surgical-spend softness as a durable trend shift. Reserve actuaries reviewing Cigna's incurred-but-not-reported estimates into the third quarter should treat the 84.5% as a genuine data point on current-period utilization rather than a number cushioned by reserve releases, but should also expect some reversion toward the guided midpoint as the back half absorbs any residual surgical volume that a strong Q2 pulled forward.

Evernorth's Rebate-Free Pivot and the Stop-Loss Pricing Question

The pharmacy side of Cigna's report carries a second, distinct pricing question. Pharmacy Benefit Services, the traditional PBM segment inside Evernorth, posted pretax adjusted earnings of $609 million, down from the prior year, which Dennison attributed to "the previously discussed renewals and extensions of large client contracts" (Cigna Q2 2026 earnings call, July 30, 2026). That decline is the visible cost of Evernorth's shift toward Signature, the rebate-free pharmacy benefit model Evernorth announced in October 2025, under which drugmaker rebates are converted into upfront point-of-sale discounts rather than retained and passed back to plan sponsors after the fact. Cigna Healthcare will adopt Signature for its fully insured commercial clients beginning in 2027, with Evernorth extending it to all pharmacy clients by 2028 (Evernorth, October 2025).

Evanko told analysts Signature "will yield margins in that 4% range... similar to what our legacy pharmacy benefit solutions products were able to deliver" (Cigna Q2 2026 earnings call, July 30, 2026), a claim that matters more for stop-loss actuaries than it might first appear. Traditional rebate-retained PBM pricing embeds a rebate guarantee into the plan sponsor's per-member-per-month cost projection, an estimate that self-funded employers and their stop-loss carriers have priced around for years. A rebate-free model removes that variable entirely, replacing a rebate guarantee (and the true-up dispute risk that comes with it) with a transparent point-of-sale price. For a specific stop-loss underwriter, that is a cleaner input: gross drug cost at the point of dispensing becomes the number that drives specific attachment exposure, rather than a net-of-rebate estimate that could differ materially from actual plan experience at the individual claimant level. The tradeoff is that self-funded employers lose the rebate dollars that, under the legacy model, partially offset the PMPM they were quoted, meaning the headline pharmacy unit cost a plan sponsor sees under Signature will typically run higher even if net plan cost is unchanged. Actuaries pricing 2027 renewals for clients migrating to Signature should expect to field exactly that question from plan sponsors comparing a higher gross Rx PMPM against a legacy PBM quote that buried the rebate offset in a separate reconciliation line.

Specialty Growth and the Generic-Substitution Cost Lever

Evernorth's Specialty and Care Services segment, the part of the pharmacy business built around specialty drug management rather than traditional PBM rebate economics, posted pretax adjusted earnings of $1,054 million, up 22% year over year, on Evernorth total revenue of $61.5 billion, itself up 6% (The Cigna Group, July 30, 2026). That growth is the offset absorbing the PBM segment's decline, and it is being driven in part by a cost-management lever with direct actuarial relevance: generic and biosimilar substitution. Dennison told analysts specialty generic penetration "exceeded 80% for newer products during the quarter," and separately flagged "moderating GLP-1 growth as coverage levels slightly declined and utilization growth slowed from elevated levels experienced in prior periods" (Cigna Q2 2026 earnings call, July 30, 2026). An 80%-plus generic conversion rate on newly genericized specialty molecules is a meaningfully faster substitution curve than the specialty pharmacy market has historically managed, and it is one of the few line items in the quarter that plausibly explains real dollar cost reduction rather than mix shift or timing.

Cigna's own commentary flagged a caveat worth carrying into 2027 planning: the magnitude of the specialty generic and biosimilar benefit in the second quarter is not expected to recur at the same level in the third and fourth quarters. That is consistent with how a generic-conversion wave typically plays out actuarially, a step-function cost reduction concentrated in the first several quarters after a molecule loses exclusivity, followed by a flatter savings profile once the addressable population has already substituted. Trend-setting actuaries who observed the Q2 magnitude of specialty generic savings should not extrapolate that pace of improvement into a 2027 pharmacy trend assumption without adjusting for the diminishing incremental substitution opportunity.

What the Split Means for 2027 Pricing and Bid Assumptions

The practical consequence of Cigna's quarter for 2027 rate-setting is that commercial group and Medicare Advantage trend assumptions need to keep diverging rather than converging toward a single industry number. PwC's Health Research Institute put the 2027 group medical cost trend at 9%, the highest reading in 17 years, driven in part by provider adoption of AI-enabled revenue optimization tools and rising pharmacy spend (PwC Health Research Institute, June 2026), a forecast this site examined in detail in its coverage of the 9% group trend benchmark. Cigna's Q2 print does not contradict that forecast so much as complicate the timing of it: a book that just posted its coolest surgical and outpatient quarter in recent memory is not obviously headed toward a 9% forward trend without some reacceleration, whether from specialty pharmacy reaccelerating, from GLP-1 coverage broadening again, or from the deferred-care catch-up resuming once member cost-sharing resets at the January 2027 plan year.

Segal's 30th annual health trend survey, published in July 2026, projected 2027 medical trend at 9.9% and prescription drug trend at 11.5%, both above the levels carriers like Cigna are currently realizing in their commercial books (see actuary.info's coverage of the Segal survey). That gap between a forward-looking survey trend and a backward-looking realized ratio is the standard actuarial tension between manual and experience rating, but it is sharper this cycle because the realized Q2 2026 data is running meaningfully below the forward assumptions multiple national surveys are converging on. For self-funded plans and their stop-loss carriers, the practical implication is to treat Cigna's 84.5% and the industry's high-single-digit forward trend surveys as describing two different things: current commercial experience and a forward-looking blend that has to underwrite for reacceleration risk, GLP-1 coverage expansion, specialty drug pipeline growth, and provider rate pressure that has not yet fully shown up in claims data. Locking a 2027 renewal off the low realized ratio alone would understate the leveraged-trend exposure that carries into specific and aggregate stop-loss attachment pricing once medical trend outpaces flat-dollar deductible growth.

The Divergence Actuaries Should Carry Forward

Cigna's quarter is a useful counterpoint to a reporting season otherwise dominated by Medicare Advantage cost-trend anxiety. UnitedHealth's improvement to 86.7%, Elevance's climb to 89.7%, and Humana's 91.2% all describe books where MA enrollment growth and Medicare fee-for-service benchmark pressure are the dominant story. Cigna's 84.5%, alongside CVS Health's Aetna posting an 87.4% medical benefit ratio on its own MA-heavy book (see this site's analysis of Aetna's 250-basis-point drop), describes a different book entirely, one where cost-sharing, faster repricing, and a completed deferred-care catch-up are doing real work. Both stories are true simultaneously, and a 2027 pricing model that applies a single blended trend assumption across commercial, MA, and ACA business lines will misprice at least one of them.

Further Reading on actuary.info

• UnitedHealth and Elevance Split the Q2 2026 Managed-Care Recovery - How UNH's ratio improved to 86.7% while Elevance's climbed 80 basis points in the same reporting window.
• Aetna's 250bp MBR Drop Rode a $471M Reserve Reversal - The reserving mechanics behind CVS Health's own Medicare Advantage-weighted improvement.
• PwC's 2027 Group Medical Cost Trend Hits 9%, a 17-Year High - The forward trend benchmark Cigna's cooler Q2 print sits against.
• Segal's 2027 Survey Pegs Medical Trend at 9.9%, With Rx Still Ahead at 11.5% - The manual-versus-experience credibility question stop-loss actuaries face heading into 2027 renewals.
• Stop-Loss's Leveraged Trend: Flat Deductibles Meet Rising Claims - The attachment-point mechanics behind why a moderating aggregate trend does not necessarily moderate specific stop-loss exposure.